Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Influenza

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    616 result(s) found for: Influenza. Displaying page 4 of 31.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-019745-25 Sponsor Protocol Number: INF-V-A005 Start Date*: 2010-08-14
    Sponsor Name:CRUCELL SWITZERLAND AG
    Full Title: A Phase III open, randomized, parallel, multi-center study in children aged 6 - 35 months to compare the immunogenicity and safety of a single 0.5 mL dose of Inflexal V with a 0.25 mL 2-dose regime...
    Medical condition: seasonal influenza vaccine
    Disease: Version SOC Term Classification Code Term Level
    9.1 10022000 PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-006563-23 Sponsor Protocol Number: CMVfluvaccinees Start Date*: 2007-02-07
    Sponsor Name:Health Protection Agency
    Full Title: A Phase IV, single group study to evaluate the immune response to licensed seasonal influenza vaccine and relationship of this to cytomegalovirus-associated immunosenescence in UK older adults aged...
    Medical condition: The vaccine is designed to provide protection against circulating influenza and is being used in the UK influnza immunisation programme 2006-7
    Disease: Version SOC Term Classification Code Term Level
    8.1 10022000 Influenza LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006263-23 Sponsor Protocol Number: ML20910 Start Date*: 2006-12-05
    Sponsor Name:ROCHE
    Full Title: Efficacy of Oseltamivir treatment in laboratory- confirmed influenza: evaluation of effect on viral shedding and on serum and cytoplasmatic inflammatory cytokine concentration.
    Medical condition: Influenza type A and B virus infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000576-19 Sponsor Protocol Number: VAP00026 Start Date*: 2022-07-29
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared with Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10059429 Influenza immunisation PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) PL (Prematurely Ended) DK (Prematurely Ended) CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023791-63 Sponsor Protocol Number: V70_34 Start Date*: 2011-03-24
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase II, Randomized, Controlled, Observer-Blind, Clinical Study to Evaluate the Humoral and Cell Mediated Immunity and Safety of Two Intramuscular Doses of Fluad® or Agrippal® in Previously Unva...
    Medical condition: influenza
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022000 Influenza LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002080-26 Sponsor Protocol Number: V58P15 Start Date*: 2013-08-28
    Sponsor Name:Novartis Vaccines & Diagnostics AG
    Full Title: A Phase III, Observer-Blind, Randomized Multicenter Study to Evaluate the Safety of Trivalent Subunit Influenza Vaccines, Produced Either in Mammalian Cell Culture (tivc) or in Embryonated Eggs (TI...
    Medical condition: volunteers at high risk for influenza-related complications (protection against influenza)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10016794 Flu vaccination LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-022817-24 Sponsor Protocol Number: OVG 2010/03 Start Date*: 2010-10-18
    Sponsor Name:University of Oxford
    Full Title: A multi-centre, open-label, clinical, phase 4 trial, following on from a head-to-head comparison study of two H1N1 influenza vaccines in children, to compare firstly, the persistence of antibody ag...
    Medical condition: Prevention of Influenza infections
    Disease: Version SOC Term Classification Code Term Level
    12.0 10059429 Influenza immunisation LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001018-13 Sponsor Protocol Number: BCX1812-305 Start Date*: 2021-03-31
    Sponsor Name:BioCryst Pharmaceuticals Inc
    Full Title: A Phase 3, Randomized, Open Label, Active-controlled Study to Evaluate the Safety, Pharmacokinetics and Effectiveness of IV Peramivir Compared to Oral Oseltamivir in Pediatric Subjects With Acute U...
    Medical condition: acute uncomplicated influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001401-25 Sponsor Protocol Number: QHD00012 Start Date*: 2019-09-27
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older
    Medical condition: Prevention of influenza infection in adults from 65 years of age and older
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003166-32 Sponsor Protocol Number: FLUVALAB-H-14 Start Date*: 2011-08-30
    Sponsor Name:Omninvest Ltd.
    Full Title: A Randomized, Double-blind, Multi-Center Study to Evaluate Safety and Immunogenicity of One Dose of Four FLUVAL AB-like (Trivalent, Whole Virus, Aluminium Phosphate Gel Adjuvanted) Influenza Vaccin...
    Medical condition: Immunization of healthy people against influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10059430 Influenza immunization LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2016-004904-74 Sponsor Protocol Number: INFQ3003 Start Date*: 2017-09-07
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: A Phase III, Observer-Blind, Randomized, Non-influenza Vaccine Comparator-Controlled, Parallel-Group, Multi-Country Study in Children Aged 6-35 Months to Assess the Safety and Efficacy of Abbott’s ...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed) EE (Ongoing) CZ (Completed) LT (Completed) BG (Completed) IT (Completed) SI (Completed) ES (Completed) FR (Not Authorised) HR (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001044-35 Sponsor Protocol Number: GQM00016 Start Date*: 2019-02-08
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 months to 17 Years
    Medical condition: Prophylaxis of influenza (Northern Hemisphere 2017-2018 season) in children aged 6 months to 17 years
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004271-22 Sponsor Protocol Number: INSIGHTPROTOCOL006 Start Date*: 2015-02-25
    Sponsor Name:Regents of the University of Minnesota
    Full Title: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Clinical Outcome Study (INSIGHT 006: FLU-IVIG)
    Medical condition: Infleunza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DK (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-003786-41 Sponsor Protocol Number: V70P5 Start Date*: 2007-10-22
    Sponsor Name:Novartis Vaccines and Diagnostics S.r.l.
    Full Title: A Phase III, randomized, observer-blind, controlled, multi-center clinical study to evaluate the efficacy, safety and immunogenicity of one and two intramuscular doses of FLUAD versus control vacci...
    Medical condition: no medical, condition: healthy,
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FI (Completed) IT (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001239-38 Sponsor Protocol Number: CP-PRO-QVLP-012 Start Date*: 2017-10-23
    Sponsor Name:Medicago R&D Inc.
    Full Title: A Randomized, Observer-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Adults 18-64...
    Medical condition: Seasonal influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-001374-34 Sponsor Protocol Number: 231 Start Date*: 2005-01-03
    Sponsor Name:Baxter Vaccine AG
    Full Title: SINGLE-BLIND RANDOMIZED CONTROLLED PHASE II/III STUDY TO INVESTIGATE THE IMMUNOGENICITY AND SAFETY AFTER A SINGLE VACCINATION WITH ONE OF THREE DIFFERENT LOTS OF AN INACTIVATED INFLUENZA VACCINE (W...
    Medical condition: Influenza Vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002883-15 Sponsor Protocol Number: V130_12 Start Date*: 2017-07-19
    Sponsor Name:Seqirus UK Limited
    Full Title: A Phase III/IV, Stratified, Randomized, Observer Blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of a Cell-Based Quadrivalent Subunit Influenza Virus Vaccine C...
    Medical condition: Profylaxis for Influenza virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: LT (Completed) EE (Completed) ES (Completed) FI (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-003933-14 Sponsor Protocol Number: RM08-3002 Start Date*: 2013-11-04
    Sponsor Name:Romark Laboratories L.C.
    Full Title: A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza
    Medical condition: acute uncomplicated influenza
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012367-34 Sponsor Protocol Number: BCX1812-301 Start Date*: 2009-11-27
    Sponsor Name:BioCryst Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of Peramivir Administered Intravenously in Addition to Standard of Care Compared to Standard o...
    Medical condition: Influenza
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) NL (Ongoing) LV (Prematurely Ended) CZ (Completed) DE (Prematurely Ended) HU (Completed) GB (Prematurely Ended) SK (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020083-38 Sponsor Protocol Number: NV25118 Start Date*: 2010-10-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Multicenter, Study of the Safety of Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged ≥13 Years
    Medical condition: Treatment of Influenza [seasonal or pandemic (H1N1) 2009]
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10022001 Influenza (epidemic) LLT
    14.0 10021881 - Infections and infestations 10022003 Influenza B virus infection LLT
    14.0 10021881 - Infections and infestations 10022000 Influenza PT
    14.0 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) LT (Prematurely Ended) DK (Prematurely Ended) FR (Ongoing) IT (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 26 07:33:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA